Akebia Therapeutics (AKBA) said Tuesday it has dosed the first patient in a phase 2 trial of its experimental drug, praliciguat, for the treatment of a rare kidney disease.
The company said the study will assess the safety and efficacy of the drug in about 60 adults with the condition who are already being treated with standard treatment.
Akebia said the primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio, a key marker of kidney damage. A key secondary endpoint is the percentage of patients achieving partial remission, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments